Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.769.125 [Categoria DeCS]
Referências encontradas : 2912 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 292 ir para página                         

  1 / 2912 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28836266
[Au] Autor:Onland W; Offringa M; van Kaam A
[Ad] Endereço:Department of Neonatology, Emma Children's Hospital AMC, University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
[Ti] Título:Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.
[So] Source:Cochrane Database Syst Rev;8:CD002311, 2017 08 24.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bronchopulmonary dysplasia (BPD), defined as oxygen dependence at 36 weeks postmenstrual age (PMA), remains an important complication of prematurity. Pulmonary inflammation plays a central role in the pathogenesis of BPD. Attenuating pulmonary inflammation with postnatal systemic corticosteroids reduces the incidence of BPD in preterm infants but may be associated with an increased risk of adverse neurodevelopmental outcomes. Local administration of corticosteroids via inhalation might be an effective and safe alternative. OBJECTIVES: To determine if administration of inhalation corticosteroids after the first week of life until 36 weeks PMA to preterm infants at high risk of developing BPD is effective and safe in reducing the incidence of death and BPD as separate or combined outcomes. SEARCH METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 4), MEDLINE via PubMed (1966 to 19 May 2017), Embase (1980 to 19 May 2017), and CINAHL (1982 to 19 May 2017). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. SELECTION CRITERIA: We included randomised controlled trials comparing inhalation corticosteroids, started ≥ 7 days postnatal age (PNA) but before 36 weeks PMA, to placebo in ventilated and non-ventilated infants at risk of BPD. We excluded trials investigating systemic corticosteroids versus inhalation corticosteroids. DATA COLLECTION AND ANALYSIS: We collected data on participant characteristics, trial methodology, and inhalation regimens. The primary outcome was death or BPD at 36 weeks PMA. Secondary outcomes were the combined outcome death or BPD at 28 days PNA, the seperate outcomes of death and BPD at both 28 days PNA, and at 36 weeks PMA, and short-term respiratory outcomes, such as failure to extubate; total days of mechanical ventilation and oxygen use; and the need for systemic corticosteroids. We contacted the original trialists to verify the validity of extracted data and to provide missing data. We analysed all data using Review Manager 5. When possible, we performed meta-analysis using typical risk ratio (RR) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes along with their 95% confidence intervals (CI). We analysed ventilated and non-ventilated participants separately.We used the GRADE approach to assess the quality of the evidence. MAIN RESULTS: We included eight trials randomising 232 preterm infants in this review. Inhalation corticosteroids did not reduce the separate or combined outcomes of death or BPD. The meta-analyses of the studies showed a reduced risk in favor of inhalation steroids regarding failure to extubate at seven days (typical RR (TRR) 0.80, 95% CI 0.66 to 0.98; 5 studies, 79 infants) and at the latest reported time point after treatment onset (TRR 0.60, 95% CI 0.45 to 0.80; 6 studies, 90 infants). However, both analyses showed increased statistical heterogeneity (I statistic 73% and 86%, respectively). Furthermore, inhalation steroids did not impact total duration of mechanical ventilation or oxygen dependency. There was a trend toward a reduction in the use of systemic corticosteroids in infants receiving inhalation corticosteroids (TRR 0.51, 95% CI 0.26 to 1.00; 4 studies, 74 infants; very low-quality evidence). There was a paucity of data on short- and long-term adverse effects. Our results should be interpreted with caution because the total number of randomised participants is relatively small, and most trials differed considerably in participant characteristics, inhalation therapy, and outcome definitions. AUTHORS' CONCLUSIONS: Based on the results of the currently available evidence, inhalation corticosteroids initiated at ≥ 7 days of life for preterm infants at high risk of developing BPD cannot be recommended at this point in time. More and larger randomised, placebo-controlled trials are needed to establish the efficacy and safety of inhalation corticosteroids.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Displasia Broncopulmonar/prevenção & controle
Glucocorticoides/administração & dosagem
Pneumonia/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Beclometasona/administração & dosagem
Displasia Broncopulmonar/etiologia
Budesonida/administração & dosagem
Dexametasona/administração & dosagem
Fluocinolona Acetonida/administração & dosagem
Fluocinolona Acetonida/análogos & derivados
Fluticasona/administração & dosagem
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Pneumonia/complicações
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Glucocorticoids); 0CD5FD6S2M (Fluocinolone Acetonide); 51333-22-3 (Budesonide); 7S5I7G3JQL (Dexamethasone); CUT2W21N7U (Fluticasone); KGZ1SLC28Z (Beclomethasone); QK4DYS664X (flunisolide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD002311.pub4


  2 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28167262
[Au] Autor:Ivey JW; Bhambri P; Church TK; Lewis DA; McDermott MT; Elbayomy S; Finlay WH; Vehring R
[Ad] Endereço:University of Alberta, Department of Mechanical Engineering, Edmonton, AB, Canada.
[Ti] Título:Humidity affects the morphology of particles emitted from beclomethasone dipropionate pressurized metered dose inhalers.
[So] Source:Int J Pharm;520(1-2):207-215, 2017 Mar 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The effects of propellant type, cosolvent content, and air humidity on the morphology and solid phase of the particles produced from solution pressurized metered dose inhalers containing the corticosteroid beclomethasone dipropionate were investigated. The active ingredient was dissolved in the HFA propellants 134a and 227ea with varying levels of the cosolvent ethanol and filled into pressurized metered dose inhalers. Inhalers were actuated into an evaporation chamber under controlled temperature and humidity conditions and sampled using a single nozzle, single stage inertial impactor. Particle morphology was assessed qualitatively using field emission scanning electron microscopy and focused ion beam-helium ion microscopy. Drug solid phase was assessed using Raman microscopy. The relative humidity of the air during inhaler actuation was found to have a strong effect on the particle morphology, with solid spheroidal particles produced in dry air and highly porous particles produced at higher humidity levels. Air humidification was found to have no effect on the solid phase of the drug particles, which was predominantly amorphous for all tested formulations. A critical level of air relative humidity was required to generate porous particles for each tested formulation. This critical relative humidity was found to depend on the amount of ethanol used in the inhaler, but not on the type of propellant utilized. The results indicate that under the right circumstances water vapor saturation followed by nucleated water condensation or ice deposition occurs during particle formation from evaporating propellant-cosolvent-BDP droplets. This finding reveals the importance of condensed water or ice as a templating agent for porosity when particle formation occurs at saturated conditions, with possible implications on the pharmacokinetics of solution pMDIs and potential applications in particle engineering for drug delivery.
[Mh] Termos MeSH primário: Aerossóis/química
Beclometasona/química
Umidade
Inaladores Dosimetrados
Tamanho da Partícula
[Mh] Termos MeSH secundário: Etanol/química
Hidrocarbonetos Fluorados/química
Pressão
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Hydrocarbons, Fluorinated); 3K9958V90M (Ethanol); KGZ1SLC28Z (Beclomethasone); R40P36GDK6 (apaflurane)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE


  3 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28065679
[Au] Autor:Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
[Ad] Endereço:University of Manchester, Medicines Evaluation Unit, The Langley Building, University Hospital of South Manchester, Southmoor Rd, Wythenshawe M23 9QZ, United Kingdom. Electronic address: DSingh@meu.org.uk.
[Ti] Título:Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
[So] Source:Pulm Pharmacol Ther;42:43-51, 2017 Feb.
[Is] ISSN:1522-9629
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some years for the management of asthma and chronic obstructive pulmonary disease (COPD). A dry powder inhaler (DPI) formulation of extrafine BDP/FF is now also available. This study evaluated the cardiovascular safety of BDP/FF DPI in comparison to BDP/FF pMDI and placebo. METHODS: Single-dose, partially-blind, randomised, placebo-controlled, 5-period crossover study. Main inclusion criteria: aged 40-75 years; moderate to severe COPD (post-bronchodilator FEV 40-80% predicted, FEV /FVC <0.7). Patients received BDP/FF 200/12, 800/48 µg and placebo via DPI, and BDP/FF 200/12 and 800/48 µg via pMDI. In both devices, 200/12 µg is the therapeutic dose; 800/48 µg is supratherapeutic. PRIMARY OBJECTIVE: to demonstrate non-inferiority between BDP/FF DPI and pMDI in average 4-h heart rate (HR ) at each dose level. Secondary variables included: HR , HR peak and individual timepoint; QTcF interval; SBP and DBP AUC ; and potassium and glucose AUC . Adverse events (AEs) were collected. RESULTS: Forty-nine patients were randomised; 45 (92%) received all five treatments. Non-inferiority was demonstrated between the DPI and pMDI formulations at both doses (-0.2 bpm [95% CI -1.3, 0.9] for 200/12 µg and 0.6 bpm [-0.5, 1.7] for 800/48 µg). Although there were statistically significant treatment-placebo differences at both doses and with both devices (thus confirming assay sensitivity), these differences were small and well below 5 bpm for the 200/12 µg dose. The results for the secondary parameters (QTcF, glucose and potassium) further supported the therapeutic equivalence of the two treatments. At the therapeutic dose, there were no clinically relevant treatment-placebo differences in any parameter with either formulation. There was no increase in the proportion of patients reporting AEs whilst receiving therapeutic doses of BDF/FF (either formulation) compared with placebo. CONCLUSIONS: Overall, this study provides reassurance over the cardiovascular safety of extrafine BDP/FF, both in a DPI and a pMDI formulation.
[Mh] Termos MeSH primário: Beclometasona/administração & dosagem
Broncodilatadores/administração & dosagem
Fumarato de Formoterol/administração & dosagem
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Idoso
Beclometasona/efeitos adversos
Broncodilatadores/efeitos adversos
Estudos Cross-Over
Combinação de Medicamentos
Inaladores de Pó Seco
Eletrocardiografia
Feminino
Volume Expiratório Forçado
Fumarato de Formoterol/efeitos adversos
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Masculino
Inaladores Dosimetrados
Meia-Idade
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Índice de Gravidade de Doença
Método Simples-Cego
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Drug Combinations); KGZ1SLC28Z (Beclomethasone); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170110
[St] Status:MEDLINE


  4 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28013164
[Au] Autor:Triolo D; Craparo EF; Porsio B; Fiorica C; Giammona G; Cavallaro G
[Ad] Endereço:Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Laboratory of Biocompatible Polymers, University of Palermo, Via Archirafi, 32, 90129 Palermo, Italy.
[Ti] Título:Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate.
[So] Source:Colloids Surf B Biointerfaces;151:206-214, 2017 Mar 01.
[Is] ISSN:1873-4367
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In this paper, the potential of novel polymeric micelles as drug delivery systems for Beclomethasone Dipropionate (BDP) administration into the lung is investigated. These nanostructures are obtained starting from α,ß-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA), which was subsequently functionalized with O-(2-aminoethyl)-O'-methylpolyethylenglycole (PEG ), ethylenediamine (EDA) and lipoic acid (LA), obtaining PHEA-PEG -EDA-LA graft copolymer. Empty and drug-loaded micelles possess adequate chemical-physical characteristics for pulmonary administration such as spherical shape, slightly positive surface charge and mean size of about 200nm. Besides, BDP-loaded micelles, obtained with a Drug Loading equal to 5wt%, result to be stable in physiological-mimicking media, protecting the drug from hydrolysis and giving a sustained drug release profile. Moreover, the micelle-like structure and surface characteristics seems to improve drug permeation through the mucus layer. Finally, it is also demonstrated that BDP-loaded PHEA-PEG -EDA-LA micelles are able to increase cell uptake of BDP of about 44wt% compared to Clenil on 16-HBE cells and possess an higher biocompatibility in comparison with the same commercial formulation.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Beclometasona/administração & dosagem
Sistemas de Liberação de Medicamentos
Pulmão/efeitos dos fármacos
Micelas
Nanopartículas/química
[Mh] Termos MeSH secundário: Antioxidantes/química
Materiais Biocompatíveis
Brônquios/citologia
Sobrevivência Celular
Portadores de Fármacos/química
Células Epiteliais/citologia
Etanol/química
Etilenodiaminas/química
Seres Humanos
Microscopia Eletrônica de Transmissão
Microscopia de Fluorescência
Tamanho da Partícula
Peptídeos/química
Propriedades de Superfície
Ácido Tióctico/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Biocompatible Materials); 0 (Drug Carriers); 0 (Ethylenediamines); 0 (Micelles); 0 (Peptides); 0 (alpha,beta-poly((2-hydroxyethyl)-aspartamide)); 3K9958V90M (Ethanol); 60V9STC53F (ethylenediamine); 73Y7P0K73Y (Thioctic Acid); KGZ1SLC28Z (Beclomethasone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170317
[Lr] Data última revisão:
170317
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161226
[St] Status:MEDLINE


  5 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28012663
[Au] Autor:Chawes B; Nilsson E; Nørgaard S; Dossing A; Mortensen L; Bisgaard H
[Ad] Endereço:COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
[Ti] Título:Knemometry is more sensitive to systemic effects of inhaled corticosteroids in children with asthma than 24-hour urine cortisol excretion.
[So] Source:J Allergy Clin Immunol;140(2):431-436, 2017 Aug.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pharmacodynamic assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measuring 24-hour urine free cortisol (UFC) excretion. Knemometry assessing short-term lower-leg growth rate (LLGR) is a more rarely used alternative. OBJECTIVE: The primary aim of this study was to compare the sensitivity of LLGR and 24-hour UFC excretion for evaluating systemic exposure to ICSs in prepubertal children with asthma. The secondary aim was to evaluate factors influencing the precision of LLGR calculated by the traditional 1 leg nonparametric method versus a new 2 leg parametric method. METHODS: The study evaluated 60 children with mild asthma aged 5 to 12 years participating in a randomized controlled trial of ICSs with longitudinal concomitant assessments of LLGR and 24-hour UFC excretion. The sensitivity of the safety assessments was analyzed by comparing LLGR and 24-hour UFC in the placebo run-in period with values in the ICS treatment period by using paired t tests. Factors with a potential influence on LLGR were analyzed by means of ANOVA and the Levene test of homogeneity. RESULTS: The mean LLGR was significantly reduced during the ICS versus placebo run-in periods: 0.18 mm/wk (SD, 0.55 mm/wk) versus 0.45 mm/wk (SD, 0.39 mm/wk), with a mean difference of 0.27 mm/wk (95% CI, 0.05-0.48 mm/wk; P = .02). In contrast, there was no difference in 24-hour UFC excretion: 6.91 nmol/mmol (SD, 4.67 nmol/mmol) versus 7.58 nmol/mmol (SD, 6.17 nmol/mmol), with a mean difference of 0.67 nmol/mmol (95% CI, -1.13 to 2.48 nmol/mmol; P = .46). We observed no significant difference in parametric determined LLGR caused by the child's age or sex, investigator, or season of measurement, whereas some differences were observed for the nonparametric LLGR. CONCLUSION: These findings suggest that knemometry is a more sensitive pharmacodynamic measure of systemic effects of ICSs than 24-hour UFC excretion and that a parametric determination of LLGR increases the sensitivity of the method. These findings should be considered by legislative authorities in the future.
[Mh] Termos MeSH primário: Corticosteroides/farmacologia
Antiasmáticos/farmacologia
Asma
Beclometasona/farmacologia
Hidrocortisona/urina
Perna (Membro)/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Administração por Inalação
Asma/urina
Criança
Desenvolvimento Infantil/efeitos dos fármacos
Pré-Escolar
Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Asthmatic Agents); KGZ1SLC28Z (Beclomethasone); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161226
[St] Status:MEDLINE


  6 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27925185
[Au] Autor:Pace E; Di Vincenzo S; Ferraro M; Siena L; Chiappara G; Dino P; Vitulo P; Bertani A; Saibene F; Lanata L; Gjomarkaj M
[Ad] Endereço:Institute of Biomedicine and Molecular Immunology, Consiglio Nazionale delle Ricerche, Palermo, Italy.
[Ti] Título:Effects of Carbocysteine and Beclomethasone on Histone Acetylation/Deacetylation Processes in Cigarette Smoke Exposed Bronchial Epithelial Cells.
[So] Source:J Cell Physiol;232(10):2851-2859, 2017 Oct.
[Is] ISSN:1097-4652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Histone deacetylase expression/activity may control inflammation, cell senescence, and responses to corticosteroids. Cigarette smoke exposure, increasing oxidative stress, may negatively affect deacetylase expression/activity. The effects of cigarette smoke extracts (CSE), carbocysteine, and beclomethasone dipropionate on chromatin remodeling processes in human bronchial epithelial cells are largely unknown. The present study was aimed to assess the effects of cigarette smoke, carbocysteine, and beclomethasone dipropionate on histone deacetylase 3 (HDAC3) expression/activity, N-CoR (nuclear receptor corepressor) expression, histone acetyltransferases (HAT) (p300/CBP) expression, p-CREB and IL-1 m-RNA expression, neutrophil chemotaxis. Increased p-CREB expression was observed in the bronchial epithelium of smokers. CSE increased p-CREB expression and decreased HDAC3 expression and activity and N-CoR m-RNA and protein expression. At the same time, CSE increased the expression of the HAT, p300/CBP. All these events increased acetylation processes within the cells and were associated to increased IL-1 m-RNA expression and neutrophil chemotaxis. The incubation of CSE exposed cells with carbocysteine and beclomethasone counteracted the effects of cigarette smoke on HDAC3 and N-CoR but not on p300/CBP. The increased deacetylation processes due to carbocysteine and beclomethasone dipropionate incubation is associated to reduced p-CREB, IL-1 m-RNA expression, neutrophil chemotaxis. These findings suggest a new role of combination therapy with carbocysteine and beclomethasone dipropionate in restoring deacetylation processes compromised by cigarette smoke exposure. J. Cell. Physiol. 232: 2851-2859, 2017. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Beclometasona/farmacologia
Brônquios/efeitos dos fármacos
Carbocisteína/farmacologia
Proteína p300 Associada a E1A/metabolismo
Células Epiteliais/efeitos dos fármacos
Histona Desacetilases/metabolismo
Histonas/metabolismo
Processamento de Proteína Pós-Traducional
Fumaça/efeitos adversos
Fumar/efeitos adversos
[Mh] Termos MeSH secundário: Acetilação
Brônquios/enzimologia
Brônquios/patologia
Linhagem Celular
Quimiotaxia de Leucócito/efeitos dos fármacos
Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo
Citoproteção
Células Epiteliais/enzimologia
Células Epiteliais/patologia
Seres Humanos
Interleucina-1/genética
Interleucina-1/metabolismo
Neutrófilos/efeitos dos fármacos
Neutrófilos/metabolismo
Correpressor 1 de Receptor Nuclear/genética
Correpressor 1 de Receptor Nuclear/metabolismo
Fosforilação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CREB1 protein, human); 0 (Cyclic AMP Response Element-Binding Protein); 0 (Histones); 0 (Interleukin-1); 0 (NCOR1 protein, human); 0 (Nuclear Receptor Co-Repressor 1); 0 (Smoke); 740J2QX53R (Carbocysteine); EC 2.3.1.48 (E1A-Associated p300 Protein); EC 2.3.1.48 (EP300 protein, human); EC 3.5.1.98 (Histone Deacetylases); EC 3.5.1.98 (histone deacetylase 3); KGZ1SLC28Z (Beclomethasone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161208
[St] Status:MEDLINE
[do] DOI:10.1002/jcp.25710


  7 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27873507
[Au] Autor:Lee YJ; Cheon JH; Kim JH; Yoo S; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH
[Ad] Endereço:Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis.
[So] Source:Yonsei Med J;58(1):144-149, 2017 Jan.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). MATERIALS AND METHODS: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. RESULTS: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). CONCLUSION: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Beclometasona/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Anti-Inflamatórios/efeitos adversos
Beclometasona/efeitos adversos
Colite Ulcerativa/tratamento farmacológico
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Feminino
Seres Humanos
Masculino
Registros Médicos
Indução de Remissão
República da Coreia
Estudos Retrospectivos
Segurança
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); KGZ1SLC28Z (Beclomethasone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161123
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2017.58.1.144


  8 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27522955
[Au] Autor:Lavorini F; Pedersen S; Usmani OS; Aerosol Drug Management Improvement Team (ADMIT)
[Ad] Endereço:Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy. Electronic address: federico.lavorini@unifi.it.
[Ti] Título:Dilemmas, Confusion, and Misconceptions Related to Small Airways Directed Therapy.
[So] Source:Chest;151(6):1345-1355, 2017 Jun.
[Is] ISSN:1931-3543
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:During the past decade, there has been increasing evidence that the small airways (ie, airways < 2 mm in internal diameter) contribute substantially to the pathophysiologic and clinical expression of asthma and COPD. The increased interest in small airways is, at least in part, a result of innovation in small-particle aerosol formulations that better target the distal lung and also advanced physiologic methods of assessing small airway responses. Increasing the precision of drug deposition may improve targeting of specific diseases or receptor locations, decrease airway drug exposure and adverse effects, and thereby increase the efficiency and effectiveness of inhaled drug delivery. The availability of small-particle aerosols of corticosteroids, bronchodilators, or their combination enables a higher total lung deposition and better peripheral lung penetration and provides added clinical benefit, compared with large-particle aerosol treatment. However, a number of questions remain unanswered about the pragmatic approach relevant for clinicians to consider the role of small airways directed therapy in the day-to-day management of asthma and COPD. We thus have tried to clarify the dilemmas, confusion, and misconceptions related to small airways directed therapy. To this end, we have reviewed all studies on small-particle aerosol therapy systematically to address the dilemmas, confusion, and misconceptions related to small airways directed therapy.
[Mh] Termos MeSH primário: Asma/tratamento farmacológico
Bronquíolos/fisiopatologia
Broncodilatadores/administração & dosagem
Glucocorticoides/administração & dosagem
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Asma/fisiopatologia
Beclometasona/administração & dosagem
Gerenciamento Clínico
Combinação de Medicamentos
Inaladores de Pó Seco
Desenho de Equipamento
Fluocinolona Acetonida/administração & dosagem
Fluocinolona Acetonida/análogos & derivados
Fumarato de Formoterol/administração & dosagem
Seres Humanos
Espaçadores de Inalação
Inaladores Dosimetrados
Nebulizadores e Vaporizadores
Tamanho da Partícula
Pregnenodionas/administração & dosagem
Pressão
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Drug Combinations); 0 (Glucocorticoids); 0 (Pregnenediones); 0CD5FD6S2M (Fluocinolone Acetonide); KGZ1SLC28Z (Beclomethasone); QK4DYS664X (flunisolide); S59502J185 (ciclesonide); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160816
[St] Status:MEDLINE


  9 / 2912 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27209586
[Au] Autor:Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
[Ad] Endereço:Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli 11/A, 43122, Parma, Italy. F.Mariotti@chiesi.com.
[Ti] Título:A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
[So] Source:Eur J Drug Metab Pharmacokinet;42(2):269-279, 2017 Apr.
[Is] ISSN:2107-0180
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: CHF 5993 is an extrafine 'triple therapy' combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting ß -agonist formoterol fumarate (FF), and the inhaled corticosteroid beclometasone dipropionate (BDP). It is in development for chronic obstructive pulmonary disease and asthma delivered via pressurised metered-dose inhaler. METHODS: This two-period, open-label, crossover study examined the drug-drug interaction of CHF 5993 and cimetidine. In one period, subjects received cimetidine 800 mg twice daily for 6 days; on the fourth day they also received CHF 5993 (BDP/FF/GB 400/24/100 µg). In the other, they received CHF 5993 alone. Primary objective was to compare the area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUC ) of GB, with and without cimetidine. Secondary endpoints included GB AUC , maximum concentration (C ), time to C (t ), elimination half-life (t ) and urinary excretion. Pharmacokinetic parameters of BDP, beclometasone-17-monopropionate (B17MP; active metabolite of BDP) and formoterol were also evaluated. RESULTS: Twenty-six subjects were randomised; 25 completed. Co-administration of CHF 5993 and cimetidine resulted in small, statistically significant increases in GB AUC , AUC and C vs CHF 5993 (ratios 1.16, 1.21 and 1.26, respectively); t , t and urinary excretion were unaffected. There were small, statistically significant increases in formoterol AUC , AUC and t following co-administration of cimetidine and CHF 5993; urinary excretion was unaffected. There were no significant differences for either BDP or B17MP. There were few adverse events (AEs), and no serious AEs. CONCLUSIONS: Overall, this study indicates that there is no clinically relevant drug-drug interaction between CHF 5993 and cimetidine.
[Mh] Termos MeSH primário: Beclometasona/farmacocinética
Cimetidina/farmacologia
Fumarato de Formoterol/farmacocinética
Glicopirrolato/farmacocinética
[Mh] Termos MeSH secundário: Administração por Inalação
Adulto
Antiasmáticos/administração & dosagem
Antiasmáticos/farmacocinética
Área Sob a Curva
Broncodilatadores/administração & dosagem
Broncodilatadores/farmacocinética
Cimetidina/administração & dosagem
Estudos Cross-Over
Combinação de Medicamentos
Interações Medicamentosas
Feminino
Fumarato de Formoterol/administração & dosagem
Glicopirrolato/administração & dosagem
Meia-Vida
Seres Humanos
Masculino
Inaladores Dosimetrados
Meia-Idade
Antagonistas Muscarínicos/administração & dosagem
Antagonistas Muscarínicos/farmacocinética
Tamanho da Partícula
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Bronchodilator Agents); 0 (Drug Combinations); 0 (Muscarinic Antagonists); 80061L1WGD (Cimetidine); KGZ1SLC28Z (Beclomethasone); V92SO9WP2I (Glycopyrrolate); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160523
[St] Status:MEDLINE
[do] DOI:10.1007/s13318-016-0345-2


  10 / 2912 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:27960245
[Au] Autor:Ng G; da Silva O; Ohlsson A
[Ad] Endereço:Department of Neonatology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, 5th Floor, Hammersmith House, Du Cane Road, London, UK, W12 0HS.
[Ti] Título:Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
[So] Source:Cochrane Database Syst Rev;12:CD003214, 2016 12 14.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic lung disease (CLD) occurs frequently in preterm infants. Bronchodilators have the potential effect of dilating small airways with muscle hypertrophy. Increased compliance and tidal volume and decreased pulmonary resistance have been documented with the use of bronchodilators in infants with CLD. Therefore, bronchodilators might have a role in the prevention and treatment of CLD. OBJECTIVES: To determine the effect of bronchodilators given as prophylaxis or as treatment for CLD on mortality and other complications of preterm birth in infants at risk for or identified as having CLD. SEARCH METHODS: On 2016 March 7, we used the standard strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 2), MEDLINE (from 1966), Embase (from 1980) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; from 1982). We searched clinical trials databases, conference proceedings and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. We applied no language restrictions. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials involving preterm infants were eligible for inclusion. Initiation of bronchodilator therapy for prevention of CLD had to occur within two weeks of birth. Treatment of patients with CLD had to be initiated before discharge from the neonatal unit. The intervention had to include administration of a bronchodilator by nebulisation, by metered dose inhaler (with or without a spacer device) or by intravenous or oral administration versus placebo or no intervention. Eligible studies had to include at least one of the following predefined clinical outcomes: mortality, CLD, number of days on oxygen, number of days on ventilator, patent ductus arteriosus (PDA), pulmonary interstitial emphysema (PIE), pneumothorax, intraventricular haemorrhage (IVH) of any grade, necrotising enterocolitis (NEC), sepsis and adverse effects of bronchodilators. DATA COLLECTION AND ANALYSIS: We used the standard method described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Two review authors extracted and assessed all data provided by each study. We reported risk ratio (RR), risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB) with 95% confidence interval (CI) for dichotomous outcomes and mean difference (MD) for continuous data. We assessed the quality of the evidence by using the GRADE approach. MAIN RESULTS: For this update, we identified one new randomised controlled trial investigating effects of bronchodilators in preterm infants. This study, which enrolled 73 infants but reported on 52 infants, examined prevention of CLD with the use of aminophylline. According to GRADE, the quality of the evidence was very low. One previously included study enrolled 173 infants to look at prevention of CLD with the use of salbutamol. According to GRADE, the quality of the evidence was moderate. We found no eligible trial that studied the use of bronchodilator therapy for treatment of individuals with CLD. Prophylaxis with salbutamol led to no statistically significant differences in mortality (RR 1.08, 95% CI 0.50 to 2.31; RD 0.01, 95% CI -0.09 to 0.11) nor in CLD (RR 1.03, 95% CI 0.78 to 1.37; RD 0.02, 95% CI -0.13 to 0.17). Results showed no statistically significant differences in other complications associated with CLD nor in preterm birth. Investigators in this study did not comment on side effects due to salbutamol. Prophylaxis with aminophylline led to a significant reduction in CLD at 28 days of life (RR 0.18, 95% CI 0.04 to 0.74; RD -0.35, 95% CI -0.56 to -0.13; NNTB 3, 95% CI 2 to 8) and no significant difference in mortality (RR 3.0, 95% CI 0.33 to 26.99; RD 0.08, 95% CI -0.07 to 0.22), along with a significantly shorter dependency on supplementary oxygen in the aminophylline group compared with the no treatment group (MD -17.75 days, 95% CI -27.56 to -7.94). Tests for heterogeneity were not applicable for any of the analyses, as each meta-analysis included only one study. AUTHORS' CONCLUSIONS: Data are insufficient for reliable assessment of the use of salbutamol for prevention of CLD. One trial of poor quality reported a reduction in the incidence of CLD and shorter duration of supplementary oxygen with prophylactic aminophylline, but these results must be interpreted with caution. Additional clinical trials are necessary to assess the role of bronchodilator agents in prophylaxis or treatment of CLD. Researchers studying the effects of bronchodilators in preterm infants should include relevant clinical outcomes in addition to pulmonary mechanical outcomes. We identified no trials that studied the use of bronchodilator therapy for treatment of CLD.
[Mh] Termos MeSH primário: Broncodilatadores/uso terapêutico
Doenças do Prematuro/prevenção & controle
Pneumopatias/prevenção & controle
[Mh] Termos MeSH secundário: Albuterol/uso terapêutico
Aminofilina/uso terapêutico
Beclometasona/uso terapêutico
Doença Crônica
Quimioterapia Combinada
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Doenças do Prematuro/mortalidade
Pneumopatias/mortalidade
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Bronchodilator Agents); 27Y3KJK423 (Aminophylline); KGZ1SLC28Z (Beclomethasone); QF8SVZ843E (Albuterol)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170207
[Lr] Data última revisão:
170207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161214
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003214.pub3



página 1 de 292 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde